← Leaderboards
David William John Armstrong
Vanderbilt University Medical Center
$427,086
Attributed
$427,086
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $130.5K · FY2022–25$200K$150K$100K$50K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$427,086 · 2
By mechanism
K99$261,036 · 1
F32$166,050 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Jonathan Harvey Soslow$5,426,669
- Evan L Brittain$13,630,303
- Douglas B Johnson$4,571,867
- Margaret Mary Samyn$902,862
- Larry W. Markham$463,617
Others in their field
Other Rising Stars on “Heart Diseases”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Michelle Rives · Baylor College Of Medicine$20,650,593
- Diana Severynse-Stevens · Research Triangle Institute$9,530,685
- James Cappo · National Jewish Health$9,298,220
- April Carson · University Of Mississippi Med Ctr$9,022,104
- Christine W Hockett · Avera Mckennan$8,908,366
Research focus
Heart DiseasesMissionDisabilityFutureInnovationMedicalCoronary FibrosisCyclic GmpExperimental StudyFoundationsHypertrophic CardiomyopathyInheritedArrhythmiaLifeCardiac Magnetic Resonance ImagingAnimal ModelAtrial Natriuretic Factor Receptor BC-Type Natriuretic PeptideAttenuatedEnzymesAdverse OutcomeFibrosisHeart FailureMouse Model
Grant awards (4)
C-type natriuretic peptide in hypertrophic cardiomyopathy$130,518
K99 · FY2025 · HL · contact PI
C-type natriuretic peptide in hypertrophic cardiomyopathy$130,518
K99 · FY2024 · HL · contact PI
Innovative natriuretic peptide-based therapy for hypertrophic cardiomyopathy$85,304
F32 · FY2023 · HL · contact PI
Innovative natriuretic peptide-based therapy for hypertrophic cardiomyopathy$80,746
F32 · FY2022 · HL · contact PI